Professor Parry Guilford
Position | Research Professor |
---|---|
Department | Department of Biochemistry |
Qualifications | MSc PhD |
Research summary | Cancer susceptibility, translational cancer research, personalised medicine |
Research
Professor Parry Guilford is the Director of the Centre for Translational Cancer Research and the Research Director of Pacific Edge Biotechnology Ltd. He completed his MSc at Otago in 1983, and his PhD at Cambridge University in 1989. His research interests include the genetics of inherited cancers, in particular gastric cancer, and the application of gene expression analysis to the diagnosis and management of cancer.
Awards
- Parry Guilford
2016, Elected as Fellow of the Royal Society of New Zealand - Parry Guilford
2016, BMS Senior Researcher Award - Chris Harris
2014, Otago Medical School Research Society's Student Science Writing Prize, 1st place
Chris's entry was entitled ‘Unlocking Prostate Cancer’. - Parry Guilford
2014, Sir Charles Hercus Medal for excellence in biomedical and health sciences
For the discovery of the gene mutation that can lead to hereditary stomach cancer in families. - Bryony Telford
2013, Otago School of Medical Sciences Postgraduate Symposium Speaking Award, 2nd place - Parry Guilford
2013, HRC Beaven Medal for Translational Research - Parry Guilford
2013, OSMS Commercialisation Award - ’translation of technological innovation to commercial reality’
- Parry Guilford
2009, James Cook Fellowship
Publications
Brewer, N., Atkinson, J., Guilford, P., Print, C., Blakely, T., & Teng, A. (2020). An estimate of limited duration cancer prevalence in New Zealand using 'big' data. New Zealand Medical Journal, 133(1514), 49-62. Retrieved from https://www.nzma.org.nz/journal
Zou, D., Day, R., Cocadiz, J. A., Parackal, S., Mitchell, W., Black, M. A., … Jackson, C., & Guilford, P. (2020). Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer. Carcinogenesis, 41(11), 1507-1517. doi: 10.1093/carcin/bgaa102
Chin, C. V., Antony, J., Ketharnathan, S., Labudina, A., Gimenez, G., Parsons, K. M., … Braithwaite, A., Guilford, P., … Horsfield, J. A. (2020). Cohesin mutations are synthetic lethal with stimulation of WNT signaling. eLIFE, 9, e61405. doi: 10.7554/eLife.61405
Blair, V. R., McLeod, M., Carneiro, F., Coit, D. G., D'Addario, J. L., van Dieren, J. M., … Paringatai, K., Bougen-Zhukov, N., Brew, T., … Godwin, T. D., … Nouri, Y., … Reeve, A. E., & Guilford, P. (2020). Hereditary diffuse gastric cancer: Updated clinical practice guidelines. Lancet Oncology, 21(8), e386-e397. doi: 10.1016/S1470-2045(20)30219-9
Norero, E., Alarcon, M. A., Hakkaart, C., de Mayo, T., Mellado, T., Garrido, M., … Guilford, P., & Corvalan, A. H. (2019). Identification of c.1531C>T pathogenic variant in the CDH1 gene as a novel germline mutation of hereditary diffuse gastric cancer. International Journal of Molecular Sciences, 20, 4980. doi: 10.3390/ijms20204980
Chapter in Book - Research
Dunbier, A. K., & Guilford, P. J. (2002). Gastric cancer: Inherited predisposition. In J. R. Bertino (Ed.), Encyclopedia of cancer. (2nd ed.) (pp. 253-258). Academic Press. [Encyclopaedia/Dictionary Entry].
Dunbier, A. K., & Guilford, P. J. (2002). Gastric cancer: Inherited predisposition. In S. R. Hamilton & L. A. Aaltonen (Eds.), Encyclopedia of Cancer, Volume 2. (2nd ed.) (pp. 253-258). USA: Elsevier Science.
Fenoglio-Preiser, C., Carneiro, F., Correa, P., Guilford, P., & et al (2000). Gastric carcinoma. In S. R. Hamilton & L. A. Aaltonen (Eds.), World Health Organization classification of tumours: Pathology and genetics of tumours of the digestive system. (pp. 39-52). Lyon, France: IARC Press.
Journal - Research Article
Brewer, N., Atkinson, J., Guilford, P., Print, C., Blakely, T., & Teng, A. (2020). An estimate of limited duration cancer prevalence in New Zealand using 'big' data. New Zealand Medical Journal, 133(1514), 49-62. Retrieved from https://www.nzma.org.nz/journal
Chin, C. V., Antony, J., Ketharnathan, S., Labudina, A., Gimenez, G., Parsons, K. M., … Braithwaite, A., Guilford, P., … Horsfield, J. A. (2020). Cohesin mutations are synthetic lethal with stimulation of WNT signaling. eLIFE, 9, e61405. doi: 10.7554/eLife.61405
Zou, D., Day, R., Cocadiz, J. A., Parackal, S., Mitchell, W., Black, M. A., … Jackson, C., & Guilford, P. (2020). Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer. Carcinogenesis, 41(11), 1507-1517. doi: 10.1093/carcin/bgaa102
Norero, E., Alarcon, M. A., Hakkaart, C., de Mayo, T., Mellado, T., Garrido, M., … Guilford, P., & Corvalan, A. H. (2019). Identification of c.1531C>T pathogenic variant in the CDH1 gene as a novel germline mutation of hereditary diffuse gastric cancer. International Journal of Molecular Sciences, 20, 4980. doi: 10.3390/ijms20204980
Hakkaart, C., Ellison-Loschmann, L., Day, R., Sporle, A., Koea, J., Harawira, P., … Guilford, P. (2019). Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand Māori. Familial Cancer, 18(1), 83-90. doi: 10.1007/s10689-018-0080-8
Beetham, H., Chen, A., Telford, B. J., Single, A., Jarman, K. E., Lackovic, K., … Guilford, P. (2019). A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells. Scientific Reports, 9, 12511. doi: 10.1038/s41598-019-48929-0
Bougen-Zhukov, N., Nouri, Y., Godwin, T., Taylor, M., Hakkaart, C., Single, A., Brew, T., Permina, E., Chen, A., Black, M. A., & Guilford, P. (2019). Allosteric AKT inhibitors target synthetic lethal vulnerabilities in E-cadherin-deficient cells. Cancers, 11(9), 1359. doi: 10.3390/cancers11091359
Parackal, S., Zou, D., Day, R., Black, M., & Guilford, P. (2019). Comparison of Roche Cell-Free DNA collection Tubes® to Streck Cell-Free DNA BCT®s for sample stability using healthy volunteers. Practical Laboratory Medicine, 16, e00125. doi: 10.1016/j.plabm.2019.e00125
Godwin, T. D., Kelly, S. T., Brew, T. P., Bougen-Zhukov, N. M., Single, A. B., Chen, A., Stylianou, C. E., … Currie, S. K., Telford, B. J., Beetham, H. G., … Black, M. A., & Guilford, P. J. (2019). E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function. Gastric Cancer, 22(2), 273-286. doi: 10.1007/s10120-018-0859-1
Ellison-Loschmann, L., Sporle, A., Corbin, M., Cheng, S., Harawira, P., Gray, M., … Guilford, P., … Pearce, N. (2017). Risk of stomach cancer in Aotearoa/New Zealand: A Māori population based case-control study. PLoS ONE, 12(7), e0181581. doi: 10.1371/journal.pone.0181581
Lotan, Y., OʼSullivan, P., Raman, J. D., Shariat, S. F., Kavalieris, L., Frampton, C., Guilford, P., … Darling, D. (2017). Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology, 35(8), 513.e15-513.e22. doi: 10.1016/j.urolonc.2017.03.008
McInnes, T., Zou, D., Rao, D. S., Munro, F. M., Phillips, V. L., McCall, J. L., Black, M. A., Reeve, A. E., & Guilford, P. J. (2017). Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer. BMC Cancer, 17, 228. doi: 10.1186/s12885-017-3226-4
Kavalieris, L., O'Sullivan, P., Frampton, C., Guilford, P., Darling, D., Jacobson, E., … Lotan, Y. (2017). Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study. Journal of Urology, 197(6), 1419-1426. doi: 10.1016/j.juro.2016.12.010
Hoeksema, K., Wee, R., Macdonald, A., Guilford, P., Wall, J., & Cornwall, J. (2017). Where to from here? Posthumous healthcare data, digital e(lectronic)-mortality and New Zealand’s healthcare future. New Zealand Medical Journal, 130(1459), 64-70. Retrieved from http://www.nzma.org.nz/journal
van der Post, R. S., Vogelaar, I. P., Carneiro, F., Guilford, P., Huntsman, D., Hoogerbrugge, N., … Fitzgerald, R. C. (2015). Hereditary diffuse gastric cancer: Updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. Journal of Medical Genetics, 52, 361-374. doi: 10.1136/jmedgenet-2015-103094
Hansford, S., Kaurah, P., Li-Chang, H., Woo, M., Senz, J., Pinheiro, H., … Guilford, P., … Huntsman, D. G. (2015). Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncology, 1(1), 23-32. doi: 10.1001/jamaoncol.2014.168
Single, A., Beetham, H., Telford, B. J., Guilford, P., & Chen, A. (2015). A comparison of real-time and endpoint cell viability assays for improved synthetic lethal drug validation. Journal of Biomolecular Screening, 20(10), 1286-1293. doi: 10.1177/1087057115605765
Telford, B. J., Chen, A., Beetham, H., Frick, J., Brew, T. P., Gould, C. M., Single, A., Godwin, T., … Guilford, P. (2015). Synthetic lethal screens identify vulnerabilities in GPCR signalling and cytoskeletal organization in E-cadherin-deficient cells. Molecular Cancer Therapeutics, 14(5), 1213-1223. doi: 10.1158/1535-7163.mct-14-1092
Chen, A., Beetham, H., Black, M. A., Priya, R., Telford, B. J., Guest, J., Wiggins, G. A. R., Godwin, T. D., … Guilford, P. J. (2014). E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. BMC Cancer, 14, 552. doi: 10.1186/1471-2407-14-552
Willson, J. S. B., Godwin, T. D., Wiggins, G. A. R., Guilford, P. J., & McCall, J. L. (2013). Primary hepatocellular neoplasms in a MODY3 family with a novel HNF1A germline mutation. Journal of Hepatology, 59(4), 904-907. doi: 10.1016/j.jhep.2013.05.024
Huang, R. Y.-J., Guilford, P., & Thiery, J. P. (2012). Early events in cell adhesion and polarity during epithelial-mesenchymal transition. Journal of Cell Science, 125(19), 4417-4422. doi: 10.1242/jcs.099697
Evans, J. J., Chitcholtan, K., Dann, J. M., Guilford, P., Harris, G., Lewis, L. K., Nagase, J., … Sykes, P. H. (2012). Adrenomedullin interacts with VEGF in endometrial cancer and has varied modulation in tumours of different grades. Gynecologic Oncology, 125(1), 214-219. doi: 10.1016/j.ygyno.2011.12.429
O'Sullivan, P., Sharples, K., Dalphin, M., Davidson, P., Gilling, P., Cambridge, L., … Luxmanan, C., … Yoon, H.-S., … Guilford, P. J. (2012). A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. Journal of Urology, 188(3), 741-747. doi: 10.1016/j.juro.2012.05.003
Nasri, S., Anjomshoaa, A., Song, S., Guilford, P., McNoe, L., Black, M., Phillips, V., Reeve, A., & Humar, B. (2010). Oligonucleotide array outperforms SNP array on formalin-fixed paraffin-embedded clinical samples. Cancer Genetics & Cytogenetics, 198(1), 1-6. doi: 10.1016/j.cancergencyto.2009.12.002
Guilford, P., Humar, B., & Blair, V. (2010). Hereditary diffuse gastric cancer: Translation of CDH1 germline mutations into clinical practice. Gastric Cancer, 13(1), 1-10. doi: 10.1007/s10120-009-0531-x
Guise, C. P., Abbattista, M. R., Singleton, R. S., Holford, S. D., Connolly, J., Dachs, G. U., Fox, S. B., Pollock, R., Harvey, J., Guilford, P., … Patterson, A. V. (2010). The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Research, 70(4), 1573-1584. doi: 10.1158/0008-5472.CAN-09-3237
Mai, P. L., Friedlander, M., Tucker, K., Phillips, K.-A., Hogg, D., Jewett, M. A. S., … Guilford, P., … Greene, M. H. (2010). The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urologic Oncology, 28(5), 492-499. doi: 10.1016/j.urolonc.2008.10.004
Fitzgerald, R. C., Hardwick, R., Huntsman, D., Carneiro, F., Guilford, P., Blair, V., … on behalf of the International Gastric Cancer Linkage Consortium. (2010). Hereditary diffuse gastric cancer: Updated consensus guidelines for clinical management and directions for future research. Journal of Medical Genetics, 47(7), 436-444. doi: 10.1136/jmg.2009.074237
Humar, B., Blair, V., Charlton, A., More, H., Martin, I., & Guilford, P. (2009). E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. Cancer Research, 69(5), 2050-2056.
Zou, D., Yoon, H.-S., Perez, D., Weeks, R. J., Guilford, P., & Humar, B. (2009). Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia. Journal of Pathology, 218(2), 265-272. doi: 10.1002/path.2541
Zou, D., Yoon, H.-S., Anjomshoaa, A., Perez, D., Fukuzawa, R., Guilford, P., & Humar, B. (2009). Increased levels of active c-Src distinguish invasive from in situ lobular lesions. Breast Cancer Research, 11(4), R45. doi: 10.1186/bcr2332
Nasri, S., More, H., Graziano, F., Ruzzo, A., Wilson, E., Dunbier, A., McKinney, C., Merriman, T., Guilford, P., … Humar, B. (2008). A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: A case control study in an Italian population. BMC Cancer, 8, 138. doi: 10.1186/1471-2407-8-138
John, T., Black, M. A., Toro, T. T., Leader, D., Gedye, C. A., Davis, I. D., Guilford, P. J., & Cebon, J. S. (2008). Predicting clinical outcome through molecular profiling in stage III melanoma. Clinical Cancer Research, 14(16), 5173-5180.
Holyoake, A., O'Sullivan, P., Pollock, R., Best, T., Watanabe, J., Kajita, Y., … da Silva Tatley, F., Cambridge, L., Toro, T., … Guilford, P. (2008). Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clinical Cancer Research, 14(3), 742-749. doi: 10.1158/1078-0432.CCR-07-1672
Linger, R., Dudakia, D., Huddart, R., Tucker, K., Friedlander, M., Phillips, K.-A., … Guilford, P., … Rapley, E. A. (2008). Analysis of the DND I gene in men with sporadic and familial testicular germ cell tumors. Genes Chromosomes & Cancer, 47(3), 247-252. doi: 10.1002/gcc.20526
Humar, B., & Guilford, P. (2008). Hereditary diffuse gastric cancer and lost cell polarity: A short path to cancer. Future Oncology, 4(2), 229-239.
Kawanishi, H., Matsui, Y., Ito, M., Watanabe, J., Takahashi, T., Nishizawa, K., … Guilford, P., Reeve, A., … Ogawa, O. (2008). Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clinical Cancer Research, 14(9), 2579-2587. doi: 10.1158/1078-0432.CCR-07-1922
Kwak, M. K., Lee, H.-J., Hur, K., Park, D. J., Lee, H. S., Kim, W. H., … Guilford, P., & Yang, H.-K. (2008). Expression of Krüppel-like factor 5 in human gastric carcinomas. Journal of Cancer Research & Clinical Oncology, 134(2), 163-167. doi: 10.1007/s00432-007-0265-2
Guilford, P., Blair, V., More, H., & Humar, B. (2007). A short guide to hereditary diffuse gastric cancer. Hereditary Cancer in Clinical Practice, 5(4), 183-194.
Matsui, S., Ito, M., Nishiyama, H., Uno, H., Kotani, H., Watanabe, J., Guilford, P., Reeve, A., … Ogawa, O. (2007). Genomic characterization of multiple clinical phenotypes of cancer using multivariate linear regression models. Bioinformatics, 23(6), 732-738.
Ito, M., Nishiyama, H., Kawanishi, H., Matsui, S., Guilford, P., Reeve, A., & Ogawa, O. (2007). P21-activated kinase 1: A new molecular marker for intravesical recurrence after transurethral resection of bladder cancer. Journal of Urology, 178, 1073-1079.
More, H., Humar, B., Weber, W., Ward, R., Christian, A., Lintott, C., … Guilford, P. (2007). Identification of seven novel germline mutations in the human E-cadherin (CDH1) gene. Human Mutation, 28(2). doi: 10.1002/humu.9473
Lin, Y.-H., Friederichs, J., Black, M. A., Mages, J., Rosenberg, R., Guilford, P. J., Phillips, V., Thompson-Fawcett, M., … van Rij, A., Yoon, H.-S., McCall, J. L., … Reeve, A. E. (2007). Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clinical Cancer Research, 13(2), 498-507. doi: 10.1158/1078-0432.CCR-05-2734
Humar, B., Fukuzawa, R., Blair, V., Dunbier, A., More, H., Charlton, A., … Reeve, A. E., … Guilford, P. (2007). Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Research, 67(6), 2480-2489. doi: 10.1158/0008-5472.CAN-06-3021
Crockford, G. P., Linger, R., Hockley, S., Dudakia, D., Johnson, L., Huddart, R., … Guilford, P., … Rapley, E. A. (2006). Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Human Molecular Genetics, 15(3), 443-451. doi: 10.1093/hmg/ddi459
Ramos-de la Medina, A., More, H., Medina-Franco, H., Humar, B., Gamboa, A., Ortiz, L. J., … Guilford, P. (2006). Single nucleotide polymorphisms (SNPs) at CDH1 promoter region in familial gastric cancer. Revista Española de Enfermedades Digestivas, 98(1), 36-41.
Blair, V., Martin, I., Shaw, D., Winship, I., Kerr, D., Arnold, J., … Cox, B., Humar, B., More, H., & Guilford, P. (2006). Hereditary diffuse gastric cancer: Diagnosis and management. Clinical Gastroenterology & Hepatology, 4, 262-275. doi: 10.1016/j.cgh.2005.12.003
Nathanson, K. L., Kanetsky, P. A., . . ., Guilford, P., & et al (2005). The Y deletion gr/gr and susceptibility to testicular germ cell tumor. American Journal of Human Genetics, 77, 1034-1043.
Shaw, D., Blair, V., Framp, A., Harawira, P., McLeod, M., & Guilford, P. (2005). Chromoendoscopic surveillance in hereditary diffuse gastric cancer: An alternative to prophylactic gastrectomy? Gut, 54, 461-468.
Charlton, A., Blair, V., Shaw, D., Parry, S., Guilford, P., & Martin, I. G. (2004). Hereditary diffuse gastric cancer: Predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut, 53, 814-820.
Rapley, E. A., Hockley, S., Warren, W., Johnson, L., Huddart, R., Crockford, G., … Guilford, P., … Stratton, M. R. (2004). Somatic mutations of KIT in familial testicular germ cell tumours. British Journal of Cancer, 90, 2397-2401. doi: 10.1038/sj.bjc.6601880
Graziano, F., Arduini, F., Ruzzo, A., Bearzi, I., Humar, B., More, H., … Guilford, P., … Cascinu, S. (2004). Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clinical Cancer Research, 10, 2784-2789.
da Silva Tatley, F. M., Aldwell, F., Dunbier, A. K., & Guilford, P. J. (2003). N-terminal E-cadherin peptides act as decoy receptors for Listeria monocytogenes. Infection & Immunity, 71(3), 1580-1583.
Humar, B., Graziano, F., Cascinu, S., Catalano, V., Ruzzo, A. M., Magnani, M., Toro, T. T., Burchill, T., Futschik, M., Merriman, T. R., & Guilford, P. J. (2002). Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene, 21, 8192-8195.
Humar, B., Toro, T. T., Graziano, F., Muller, H., Dobbie, Z., Kwang-Yang, H., … Merriman, T. R., & Guilford, P. J. (2002). Novel Germline CDH1 mutations in hereditary diffuse gastric cancer families. Human Mutation, 19, 518-525.
Pharoah, P. D., Guilford, P. J., & Caldas, C. (2001). Incidence of gastric cancer and breast cancer in CDH1 (E-Cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology, 121, 1348-1353.
Chun, Y. S., Lindor, N. M., Smyrk, T. C., Petersen, B. T., Burgart, L. J., Guilford, P. J., & Donohue, J. H. (2001). Germline E-cadherin gene mutations - Is prophylactic total gastrectomy indicated? Cancer, 92(1), 181-187.
Dunbier, A. K., & Guilford, P. J. (2001). Hereditary diffuse gastric cancer. Advances in Cancer Research, 83, 55-65.
Grady, W. M., Willis, J., Guilford, P. J., Dunbier, A. K., Toro, T. T., Lynch, H., … Markowitz, S. D. (2000). Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nature Genetics, 26, 16-17.
Guilford, P. J. (2000). The inherited susceptibility to cancer. Cellular & Molecular Life Sciences, 57, 589-603.
Gardner, R. J. M., Gaff, C. L., Macrae, F. A., St John, D. J. B., Hopkins, J., Guilford, P. J., & Reeve, A. E. (1999). E-cadherin unlikely to be a common "low penetrance" gene for colorectal cancer. American Journal of Medical Genetics, 84(2), 169-171.
Shinmura, K., Kohno, T., Takahashi, M., Sasaki, A., Ochiai, A., Guilford, P., Hunter, A. K., Reeve, A. E., … Yokota, J. (1999). Familial gastric cancer: Clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. Carcinogenesis, 20(6), 1127-1131. doi: 10.1093/carcin/20.6.1127
Guilford, P. J., Hopkins, J. B. W., Grady, W. M., Markowitz, S. D., Willis, J., Lynch, H., … Toro, T. T., … Shaw, D. P., Findlay, M. P. N., & Reeve, A. E. (1999). E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Human Mutation, 14(3), 249-255. doi: 10.1002/(SICI)1098-1004
Guilford, P., Hopkins, J. B. W., Harraway, J., McLeod, M., McLeod, N., Harawira, P., … Miller, A., & Reeve, A. E. (1998). E-cadherin germline mutations in familial gastric cancer. Nature, 392(6674), 402-405. doi: 10.1038/32918
Choi, K.-L., McNoe, L. A., French, M. C., Guilford, P. J., & Eccles, M. R. (1998). Absence of PAX2 gene mutations in patients with primary familial vesicoureteric reflux. Journal of Medical Genetics, 35(4), 338-339. doi: 10.1136/jmg.35.4.338
Guilford, P., Prakash, S., Zhu, J. M., Rikkerink, E., Gardiner, S., Bassett, H., & Forster, R. (1997). Microsatellites in Malus X domestica (apple): Abundance, polymorphism and cultivar identification. Theoretical & Applied Genetics, 94(2), 249-254. doi: 10.1007/s001220050407
Guilford, P., Dode, C., Crozet, F., Blanchard, S., Chaib, H., Levilliers, J., … Petit, C. (1995). A YAC contig and an EST map in the pericentromeric region of chromosome 13q surrounding the loci for neurosensory non-syndromic deafness (DFNB1 and DFNA3) and the limb-girdle muscular dystrophy type 2C (LGMD2C). Genomics, 29(1), 163-169. doi: 10.1006/geno.1995.1227
Journal - Research Other
Blair, V. R., McLeod, M., Carneiro, F., Coit, D. G., D'Addario, J. L., van Dieren, J. M., … Paringatai, K., Bougen-Zhukov, N., Brew, T., … Godwin, T. D., … Nouri, Y., … Reeve, A. E., & Guilford, P. (2020). Hereditary diffuse gastric cancer: Updated clinical practice guidelines. Lancet Oncology, 21(8), e386-e397. doi: 10.1016/S1470-2045(20)30219-9
Figueiredo, J., Melo, S., Carneiro, P., Moreira, A. M., Fernandes, M. S., Ribeiro, A. S., Guilford, P., … Seruca, R. (2019). Clinical spectrum and pleiotropic nature of CDH1 germline mutations. Journal of Medical Genetics, 56, 199-208. doi: 10.1136/jmedgenet-2018-105807
van der Post, R. S., Oliveira, C., Guilford, P., & Carneiro, F. (2019). Hereditary gastric cancer: What's new? Update 2013-2018. Familial Cancer, 18, 363-367. doi: 10.1007/s10689-019-00127-7
Figueiredo, J., Melo, S., Gamet, K., Godwin, T., Seixas, S., Sanches, J. M., Guilford, P., & Seruca, R. (2018). E-cadherin signal sequence disruption: A novel mechanism underlying hereditary cancer. Molecular Cancer, 17, 112. doi: 10.1186/s12943-018-0859-0
Cornwall, J., Slatter, T., Guilford, P., Print, C. G., Henaghan, M., & Wee, R. (2014). Culture, law, ethics, and social implications: Is society ready for advanced genomic medicine? Australasian Medical Journal, 7(4), 200-202. doi: 10.4066/amj.2014.2069
Humar, B., & Guilford, P. (2009). Hereditary diffuse gastric cancer: A manifestation of lost cell polarity. Cancer Science, 100(7), 1151-1157. doi: 10.1111/j.1349-7006.2009.01163.x
Graziano, F., Humar, B., & Guilford, P. J. (2003). The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: From the laboratory to clinical practice. Annals of Oncology, 14, 1705-1713.
Park, J.-G., Yang, H.-K., Kim, W. H., Caldas, C., Yokota, J., & Guilford, P. J. (2000). Report on the First Meeting of the International Collaborative Group on Hereditary Gastric Cancer. Journal of the National Cancer Institute, 92(21), 1781-1782.